Related Experiment Video
Updated: Mar 13, 2026
04:44
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
21.0K
RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis.
Oliver Distler1, Janet Pope2, Chris Denton3
1Division of Rheumatology, University Hospital, Zurich, Switzerland.
Respiratory Medicine
|October 18, 2016
Summary
This study evaluated riociguat for diffuse cutaneous systemic sclerosis (dcSSc). While results are pending, riociguat shows potential for treating SSc by targeting fibrosis and proliferation.
Area of Science:
- Rheumatology
- Clinical Pharmacology
Background:
- Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by fibrosis.
- Riociguat, a stimulator of soluble guanylate cyclase, has shown efficacy in pulmonary hypertension and possesses antiproliferative and antifibrotic properties in preclinical models.
Purpose of the Study:
- To investigate the efficacy and safety of riociguat in patients with diffuse cutaneous systemic sclerosis (dcSSc).
- To assess the impact of riociguat on skin fibrosis, quality of life, and organ function in SSc patients.
Main Methods:
- A randomized, double-blind, placebo-controlled phase 2 study (RISE-SSc, NCT02283762).
- Patients with early dcSSc received riociguat (up-titrated to 2.5 mg TID) or placebo for 52 weeks.
- Primary endpoint: change in modified Rodnan skin score (mRSS) at 52 weeks. Secondary endpoints included quality of life, digital ulcers, and lung function.
Main Results:
- Data on efficacy and safety are currently being collected and analyzed.
- The study is designed to provide insights into riociguat's potential as a novel therapeutic agent for SSc.
Conclusions:
- Riociguat is being investigated for its potential to treat diffuse cutaneous systemic sclerosis based on its antifibrotic and antiproliferative mechanisms.
- The RISE-SSc study will provide critical data on the clinical utility of riociguat in managing SSc complications.
Related Concept Videos
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
724
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
724
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
579
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
579
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
593
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
593
01:15Reticular Dermis
5.4K
The papillary and reticular dermis are the two layers of the dermis. They are made of connective tissue with fibers of collagen extending from one to the other, making the border between the two somewhat indistinct. The dermal papillae extending into the epidermis belong to the papillary layer, whereas the dense collagen fiber bundles below belong to the reticular layer.
Reticular Layer
Underlying the papillary layer is the much thicker reticular layer, composed of dense, irregular connective...
Reticular Layer
Underlying the papillary layer is the much thicker reticular layer, composed of dense, irregular connective...
5.4K
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
1.8K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.8K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
893
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
893